AU2006332212B8 - Combination therapy using anti-EGFR and anti-HER2 antibodies - Google Patents

Combination therapy using anti-EGFR and anti-HER2 antibodies Download PDF

Info

Publication number
AU2006332212B8
AU2006332212B8 AU2006332212A AU2006332212A AU2006332212B8 AU 2006332212 B8 AU2006332212 B8 AU 2006332212B8 AU 2006332212 A AU2006332212 A AU 2006332212A AU 2006332212 A AU2006332212 A AU 2006332212A AU 2006332212 B8 AU2006332212 B8 AU 2006332212B8
Authority
AU
Australia
Prior art keywords
her2
egfr
antibody
tumor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006332212A
Other languages
English (en)
Other versions
AU2006332212A1 (en
AU2006332212B2 (en
Inventor
David Azria
Stephen D. Gillies
Christel Larbouret
Andre Pelegrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006332212(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of AU2006332212A1 publication Critical patent/AU2006332212A1/en
Assigned to L'INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE reassignment L'INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Request for Assignment Assignors: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER, L'INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, MERCK PATENT GMBH, UNIVERSITY OF MONTPELLIER 1
Application granted granted Critical
Publication of AU2006332212B2 publication Critical patent/AU2006332212B2/en
Publication of AU2006332212B8 publication Critical patent/AU2006332212B8/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006332212A 2006-01-04 2006-12-15 Combination therapy using anti-EGFR and anti-HER2 antibodies Ceased AU2006332212B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06000107.0 2006-01-04
EP06000107 2006-01-04
PCT/EP2006/012133 WO2007076923A1 (en) 2006-01-04 2006-12-15 Combination therapy using anti-egfr and anti-her2 antibodies

Publications (3)

Publication Number Publication Date
AU2006332212A1 AU2006332212A1 (en) 2007-07-12
AU2006332212B2 AU2006332212B2 (en) 2013-03-28
AU2006332212B8 true AU2006332212B8 (en) 2013-05-30

Family

ID=37876938

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006332212A Ceased AU2006332212B8 (en) 2006-01-04 2006-12-15 Combination therapy using anti-EGFR and anti-HER2 antibodies

Country Status (13)

Country Link
US (2) US20090214541A1 (https=)
EP (1) EP1968633B2 (https=)
JP (1) JP2009522316A (https=)
KR (1) KR20080110987A (https=)
CN (1) CN101365486B (https=)
AR (1) AR059127A1 (https=)
AU (1) AU2006332212B8 (https=)
BR (1) BRPI0620888A2 (https=)
CA (1) CA2636074A1 (https=)
EA (1) EA015173B1 (https=)
MX (1) MX2008008564A (https=)
WO (1) WO2007076923A1 (https=)
ZA (1) ZA200806723B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
WO2008027236A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2542152T3 (es) 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
CN102143977B (zh) * 2008-09-03 2014-08-06 霍夫曼-拉罗奇有限公司 多特异性抗体
US8883149B2 (en) 2008-09-15 2014-11-11 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
US8728479B2 (en) * 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
EP2844675B1 (en) 2012-05-02 2019-01-02 Symphogen A/S Humanized pan-her antibody compositions
WO2014160336A1 (en) * 2013-03-13 2014-10-02 University Of Kentucky Research Foundation METHODS OF ADMINISTERING IgG1 ANTIBODIES AND METHODS OF SUPPRESSING ANGIOGENESIS
WO2014139131A1 (en) 2013-03-14 2014-09-18 Crown Bioscience, Inc. Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
EP3019531A4 (en) * 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunoglobulin fusion proteins and compositions thereof
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
MY193723A (en) * 2014-08-29 2022-10-27 Hoffmann La Roche Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
CN104991065B (zh) * 2015-07-07 2017-01-11 复旦大学附属金山医院 一种用于诊断乳腺癌的三联标志物及其应用
JP2018062980A (ja) * 2016-10-12 2018-04-19 株式会社ジェイテクト ボールネジ装置、ボールネジ装置の製造方法及びステアリング装置
AU2017387909A1 (en) * 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
CN117915950A (zh) * 2021-08-06 2024-04-19 甘李药业股份有限公司 一种多特异性抗体及其用途
CN117430707B (zh) * 2023-10-25 2024-04-19 重庆天科雅生物科技有限公司 一种cik细胞的制备方法及其在治疗癌症中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270765B1 (en) * 1995-06-07 2001-08-07 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
WO2004032961A1 (en) * 2002-10-10 2004-04-22 Merck Patent Gmbh Bispecific anti-erb-b antibodies and their use in tumor therapy
WO2007013950A2 (en) * 2005-07-22 2007-02-01 Genentech, Inc. Combination therapy of her expressing tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
RU2390353C2 (ru) * 2004-02-12 2010-05-27 Мерк Патент Гмбх Высококонцентрированные жидкие композиции анти-egfr антител

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270765B1 (en) * 1995-06-07 2001-08-07 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
WO2004032961A1 (en) * 2002-10-10 2004-04-22 Merck Patent Gmbh Bispecific anti-erb-b antibodies and their use in tumor therapy
WO2007013950A2 (en) * 2005-07-22 2007-02-01 Genentech, Inc. Combination therapy of her expressing tumors

Also Published As

Publication number Publication date
JP2009522316A (ja) 2009-06-11
BRPI0620888A2 (pt) 2011-11-29
US9522956B2 (en) 2016-12-20
ZA200806723B (en) 2009-09-30
CN101365486B (zh) 2012-10-31
EP1968633A1 (en) 2008-09-17
EP1968633B2 (en) 2017-11-01
CN101365486A (zh) 2009-02-11
CA2636074A1 (en) 2007-07-12
EA200870141A1 (ru) 2009-02-27
WO2007076923A1 (en) 2007-07-12
AU2006332212A1 (en) 2007-07-12
EP1968633B1 (en) 2014-02-12
AR059127A1 (es) 2008-03-12
MX2008008564A (es) 2009-01-29
KR20080110987A (ko) 2008-12-22
US20150132308A1 (en) 2015-05-14
US20090214541A1 (en) 2009-08-27
AU2006332212B2 (en) 2013-03-28
EA015173B1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
US9522956B2 (en) Combination therapy using anti-EGFR and anti-HER2 antibodies
KR101088661B1 (ko) Ｅｒｂ－ｂ１ 수용체를 표적으로 하는 약학적 조성물
JP6325527B2 (ja) ヒト化ｐａｎ−ｈｅｒ抗体組成物
KR20140026337A (ko) Ｐａｎ―ｈｅｒ 항체 조성물
KR20200018785A (ko) 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합
IL300388A (en) Treatment with drug-conjugated antibodies specific for the HER2 site
JP7304815B2 (ja) Ｅｒｂｂ－２、ｅｒｂｂ－２／ｅｒｂｂ－３陽性腫瘍を有する個体の処置のための、ｅｒｂ－２及びｅｒｂｂ－３の細胞外部分上のエピトープに結合する抗原結合部位を含むｅｒｂｂ－２標的化剤及び二重特異性抗体
CN100408097C (zh) 双特异性抗erb-b抗体及其在肿瘤治疗中的用途
CN121622921A (zh) Her2 adc药物组合物及其用途
EP4005593A1 (en) Multivariable dosing method for use in treating high-egfr expression cancer
KR20250148463A (ko) 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체
HK1081449B (en) Pharmaceutical compositions directed to erb-b1 receptors
HK1081448B (en) Bispecific anti-erb-b antibodies and their use in tumor therapy
ZA200503706B (en) Pharmaceutical compositions directed to Erb-B1 receptors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: L INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE

Free format text: FORMER APPLICANT(S): L INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ; UNIVERSITY OF MONTPELLIER 1 ; MERCK PATENT GMBH ; CENTRE REGIONAL DE LUTTE CONTRE LE CANCER

TH Corrigenda

Free format text: IN VOL 27 , NO 12 , PAGE(S) 1645 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME L INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, APPLICATION NO. 2006332212, UNDER INID (71) CORRECT THE APPLICANT NAME TO INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired